228 related articles for article (PubMed ID: 26718275)
21. The risky business of drug development in neurology.
Craven R
Lancet Neurol; 2011 Feb; 10(2):116-7. PubMed ID: 21256451
[No Abstract] [Full Text] [Related]
22. The long march of antisense.
Jones D
Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
[No Abstract] [Full Text] [Related]
23. Eyes on new product development.
Novack GD
J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
[No Abstract] [Full Text] [Related]
24. Jay Bradner.
Nat Rev Drug Discov; 2017 Mar; 16(4):232-233. PubMed ID: 28356589
[No Abstract] [Full Text] [Related]
25. The role of discovery DMPK scientists in industry: where do we go from here?
Moriwaki T
Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22666880
[No Abstract] [Full Text] [Related]
26. Mark Fishman. Interview by Asher Mullard.
Fishman M
Nat Rev Drug Discov; 2012 Jan; 11(1):14-5. PubMed ID: 22212670
[No Abstract] [Full Text] [Related]
27. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
Vallance P; Williams P; Dollery C
Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
[No Abstract] [Full Text] [Related]
28. A bitter pill.
Nat Chem; 2010 May; 2(5):337. PubMed ID: 20414223
[No Abstract] [Full Text] [Related]
29. What matters most in commercial success: first-in-class or best-in-class?
Schulze U; Ringel M
Nat Rev Drug Discov; 2013 Jun; 12(6):419-20. PubMed ID: 23722339
[No Abstract] [Full Text] [Related]
30. Picking up the pieces with FBDD or FADD: invest early for future success.
Whittaker M
Drug Discov Today; 2009 Jul; 14(13-14):623-4. PubMed ID: 19486947
[No Abstract] [Full Text] [Related]
31. How artificial intelligence is changing drug discovery.
Fleming N
Nature; 2018 May; 557(7707):S55-S57. PubMed ID: 29849160
[No Abstract] [Full Text] [Related]
32. Open access chemical and clinical probes to support drug discovery.
Edwards AM; Bountra C; Kerr DJ; Willson TM
Nat Chem Biol; 2009 Jul; 5(7):436-40. PubMed ID: 19536100
[TBL] [Abstract][Full Text] [Related]
33. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.
Lee JA; Uhlik MT; Moxham CM; Tomandl D; Sall DJ
J Med Chem; 2012 May; 55(10):4527-38. PubMed ID: 22409666
[No Abstract] [Full Text] [Related]
34. Cancer charity sees success re-prioritizing industry's shelved compounds.
Mullard A
Nat Rev Drug Discov; 2014 May; 13(5):319-21. PubMed ID: 24781536
[No Abstract] [Full Text] [Related]
35. Buy buy bispecific antibodies.
Holmes D
Nat Rev Drug Discov; 2011 Oct; 10(11):798-800. PubMed ID: 22037028
[No Abstract] [Full Text] [Related]
36. Precompetitive activity to address the biological data needs of drug discovery.
Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M
Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293
[No Abstract] [Full Text] [Related]
37. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
Woosley RL; Myers RT; Goodsaid F
Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
[TBL] [Abstract][Full Text] [Related]
38. Interview with Lisa Shipley. Interviewed by Lisa Parks.
Shipley L
Bioanalysis; 2013 Aug; 5(15):1819-20. PubMed ID: 23905854
[TBL] [Abstract][Full Text] [Related]
39. The Art of Virtualizing Pharma R&D.
Schuhmacher A; Gassmann O; Kuss M; Hinder M
Drug Discov Today; 2019 Nov; 24(11):2105-2107. PubMed ID: 31323393
[No Abstract] [Full Text] [Related]
40. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
